Equities research analysts at Berenberg Bank initiated coverage on shares of UCB (OTCMKTS:UCBJF) in a research note issued to investors on Wednesday, The Fly reports. The brokerage set a “buy” rating on the stock.
Several other analysts have also recently issued reports on the stock. UBS Group raised shares of UCB to a “buy” rating and set a $116.00 price target on the stock in a report on Monday, August 23rd. Barclays lowered shares of UCB to a “hold” rating and set a $91.00 price target for the company. in a research report on Tuesday, October 19th. JPMorgan Chase & Co. raised shares of UCB to a “buy” rating and set a $150.00 price objective for the company in a report on Thursday, September 2nd. Finally, Jefferies Financial Group raised shares of UCB to a “buy” rating and set a $130.00 price target for the company in a report on Thursday, September 16th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $116.77.
Shares of UCBJF stock opened at $115.75 on Wednesday. The firm’s 50 day moving average price is $114.13 and its two-hundred day moving average price is $106.99. UCB has a fifty-two week low of $93.00 and a fifty-two week high of $120.25. The company has a quick ratio of 0.86, a current ratio of 1.23 and a debt-to-equity ratio of 0.26.
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Featured Story: What moving averages are used to define a golden cross?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.